Navigation Links
Nasal mucosal inhalation of AD vaccine attenuates Aβ1-42-induced cytotoxicity
Date:7/9/2014

Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can alleviate the symptoms of Alzheimer's disease, but fail to affect irreversible cognitive dysfunction and effectively scavenge amyloid beta peptide in the brain. Amyloid beta peptide (Aβ) vaccines reduced and eliminated Aβ deposition in an Alzheimer's disease (AD) transgenic mouse model, and significantly improved behavioral and cognitive impairment. Dr. Yunpeng Cao and his team, First Affiliated Hospital of China Medical University, China immunized AD transgenic mouse models with Plp-Adeno-X-CMV-(Aβ3-10)10-CpG via nasal mucosal inhalation. They found that Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can produce strong T helper 2 humoral immune responses, and avoid Aβ1-42-caused T helper 1 immune responses and Aβ1-42-induced cytotoxicity. Therefore, Plp-Adeno-X-CMV-(Aβ3-10)10-CpG vaccine can be used as a novel type of AD vaccine. These findings were published in Neural Regeneration Research (Vol. 9, No. 8, 2014).


'/>"/>

Contact: Meng Zhao
eic@nrren.org
86-138-049-98773
Neural Regeneration Research
Source:Eurekalert

Page: 1

Related biology news :

1. Intranasal neuropeptide Y may offer therapeutic potential for post-traumatic stress disorder
2. AcelRx Pharmaceuticals Receives First U.S. Patent for Small-Volume Oral Transmucosal Dosage Forms
3. First positive results toward a therapeutic vaccine against brain cancer
4. Researchers shut down a SARS cloaking system; findings could lead to SARS, MERS vaccines
5. UNL team explores new approach to HIV vaccine
6. Ebola vaccine success highlights dilemma of testing on captive chimps to save wild apes
7. New experimental vaccine produces immune response against MERS virus
8. New technique brings us closer to HIV and Hepatitis C vaccines
9. Potential lung cancer vaccine shows renewed promise
10. Researchers have identified a novel immunological mechanism of great importance for vaccine developm
11. Can personalized tumor vaccines improve interleukin-2 treated metastatic melanoma?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Since its launch in December 2014, the ... the pain of trying to remember their usernames and passwords ... to their smartphones. To assist people who have struggled to ... that created 1U and focuses on redefining identity, announced today ...
(Date:12/19/2014)... Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced the ... Apple/AuthenTec TMDR92 & Sapphire - Technology Report" report ... Following the acquisition of AuthenTec in ... the iPhone 5S. It is currently the only device ...
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 Based on ... Samsung introduces for the first time a fingerprint sensor ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... - Researchers are developing new technologies that combine ... and tiny particles such as bacteria, viruses and ... drug manufacturing to food safety. The technologies ... "lab-on-a-chip" applications, or miniature instruments that perform measurements ...
... shown that, from the time that a woman starts trying ... on the time to pregnancy. Professor Roger Hart told ... and Embryology that the negative effect of gum disease on ... effect of obesity. Periodontal (gum) disease is a ...
... to the deserts of East Africa and has unique physical traits ... It has a lack of pain sensation in its skin ... underground with limited oxygen supply. For the first ... understand its longevity and resistance to diseases of ageing. Researchers ...
Cached Biology News:Laser, electric fields combined for new 'lab-on-chip' technologies 2Laser, electric fields combined for new 'lab-on-chip' technologies 3Gum disease can increase the time it takes to become pregnant 2Gum disease can increase the time it takes to become pregnant 3Scientists sequence DNA of cancer-resistant rodent 2
(Date:1/22/2015)... 22, 2015   Cypher Genomics, Inc., the ... SQNM ), the leading molecular diagnostics ... generation noninvasive prenatal tests (NIPT). Through this agreement, ... Mantis™, to advance analysis of clinically-relevant fetal sub-chromosomal ...
(Date:12/24/2014)... 2014  United Therapeutics Corporation (NASDAQ: UTHR ) ... ) has submitted a pre-market approval application to the ... of Medtronic,s SynchroMed ® II implantable drug infusion ... United Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously ...
(Date:12/24/2014)... St. Louis, Missouri (PRWEB) December 23, 2014 ... Swiss biotechnology company, Syngenta, are in the process of being ... consolidated case is In Re: Syngenta AG MIR 162 Corn ... the District of Kansas. , Management of the Syngenta GMO ...
(Date:12/24/2014)... The report provides basic information on ... and industry overview. This report also presents product ... is separated by regions, technology and applications. The ... client survey, marketing channels, industry development trend and ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... GeneLink BioSciences, Inc. (OTC Bulletin Board: GNLK, ... www.helixlife.com ), a private label distribution partnership serving the ... CEO, stated, "HelixLife gives GeneLink reach into new areas ... have not been available to us.  The HelixLife team ...
... September 24, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... scientists have spent the past 40 years describing the ... cell divides into two, they still haven,t agreed on ... contradictory theories, which now may be reconciled by a ... You. These findings could provide insights into the initiation ...
Cached Biology Technology:GeneLink Announces HelixLife Private Label Distribution Agreement 252-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 252-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 352-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 452-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 552-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 652-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 752-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 852-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 952-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1052-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 1152-Week Phase 3 Study Found Investigational Drug Dapagliflozin Plus Metformin Similar to Glipizide Plus Metformin in Improving Glycosylated Hemoglobin (HbA1c) in Adults with Type 2 Diabetes Mellitus 12Genetic switch underlies noisy cell division 2
... ZMD.358. Immunogen: Synthetic peptide ... of human mouse and rat ... human and mouse LRP5 proteins. ... controls: mouse LRP5-pSEC-tag-transfected 293T cells ...
MarrowMAX Bone Marrow Medium...
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
Rabbit anti-phospho-EGFr (Tyr992) - Concentrate...
Biology Products: